A Phase 1, Single-Center, Double-Blind, Placebo Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ABP-700 after a Single Ascending Bolus Dose

Completed

• Conditions: anesthesia; Not applicable

• Registration Number: NL-OMON40883
• Lead Sponsor: Annovation Biopharma, Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

Healthy men and/or women between 18 and 45 years of age (inclusive)

Exclusion Criteria

Clinical significant abnormalities at medical research

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Safety, PK and PD</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable.</p><br>